Cellevate: €5.48m (in total)

Case

6/7/22

GAEU Consulting supports Cellevate in securing the EIC Accelerator funding. We are proud to share yet another success in the Horizon Europe, EIC Accelerator program. Our dear Client, Cellevate AB from Lund, Sweden has received a grant of EUR 5.48m (in total) to accelerate the development and commercialisation of Cellevat3d™ Microcarriers. Cellevate develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3d™ - with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing.

Tomasz Wąsik comments: “we have once again proven the capabilities of our team to support complex deep tech projects with potential to shake the legacy grounds in the life science industry. Through this challenging application process, we have built a fantastic relationship with Cellevate team – I dare to say we have become one project family that understands each other without words. Thank you Laura, Max and Harald! In my team, I would like to say big thank you to Joanna for organising our work and the quality control processes, Kamil for being the scientific mastermind behind this proposal, Jerzy for building the world class financial model and Patrycja for making the application beautiful.”

Laura Chirica, CEO Cellevate comments: ”Working with GAEU Consulting throughout the whole application process from the definition of the innovative proposal to the financial project overview and the growth forecast, has been crucial for us! This collaboration has led to Cellevate being awarded 5.48 MEUR (in total) from EIC Accelerator for large-scale commercialization of our game changing nanofiber-based Cellevat3d Microcarrier.
The GAEU team combines unique sets of skills by offering scientific and technical expertise together with project management and extremely solid financial analysis and funding/capital investment knowledge. Furthermore, they are wonderful people, very professional in their approach and always ready to support us whenever we needed them!”

Previous
Previous

Genagon: €500k

Next
Next

Elicera Therapeutics AB (publ): €2.5m